Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00325
|
|||||
| Drug Name |
Acyclovir
|
|||||
| Synonyms |
2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 2-Amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 6H-Purin-6-one,2-amino-1,9-dihydro-9-((2-hydroxyethoxy)mehtyl); 9-((2-Hydroxyethoxy)methyl)guanine; 9-(2-Hydroxyethoxy)methylguanine; 9-HYROXYETHOXYMETHYLGUANINE; 9-[(2-Hydroxyethoxy)-methyl]guanine; 9-[(2-Hydroxyethoxy)methyl]guanine; A 4669; ACV; ACV & Pluronic F-68; Aciclovier; Aciclovir (JAN/INN); Aciclovir, Acycloguanosine, Zovirax, Acyclovir; Aciclovirum; Aciclovirum [INN-Latin]; Aciclovirum [Latin]; Acivir (TN); Acivirax (TN); Activir; AcycloFoam; Acycloguanosine; Acyclovir; Acyclovir & Pluronic F-68; Acyclovir (USP); Acyclovir Lauriad; Acyclovir [USAN]; Acyclovir-side chain-2-3H; Alti-Acyclovir; Avirax; B-LF& ACV; BW-248-U; BW-248U; BW-248U74; Bovine lactoferrin & 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; Cyclovir (TN); DRG-0008; Genvir; Hascovir; Herpex (TN); Maynar; Vipral; Virolex; Viropump; Virorax; W-248-U; Wellcome-248U; Zovir; Zovir (TN); Zovirax; Zovirax (TN); Zovirax Oral Acyclovir (ACV) Suspension
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Herpes simplex virus infection [ICD11: 1F00] | Approved | [1] | |||
| Chickenpox [ICD11: 1.00E+90] | Approved | [1] | ||||
| Shingles [ICD11: 1.00E+91] | Approved | [1] | ||||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H11N5O3
|
|||||
| Canonical SMILES |
C1=NC2=C(N1COCCO)N=C(NC2=O)N
|
|||||
| InChI |
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
|
|||||
| InChIKey |
MKUXAQIIEYXACX-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 59277-89-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 225.2 | Topological Polar Surface Area | 115 | ||
| Heavy Atom Count | 16 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-1.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321108
, 10589392
, 11110742
, 11110743
, 11335360
, 11360599
, 11364633
, 11367195
, 11369757
, 11372947
, 11374028
, 11377919
, 11461571
, 11466114
, 11467234
, 11485202
, 11485687
, 11489379
, 11491689
, 11492040
, 11495553
, 11528717
, 12013356
, 14773677
, 15172245
, 15220533
, 17404601
, 1916590
, 24278078
, 24890562
, 25621755
, 26612492
, 26679648
, 26747423
, 26747424
, 502278
, 5344000
, 5344001
, 594925
, 603044
, 6855606
, 7847289
, 7885662
, 794369
, 7978637
, 8150001
, 8151390
, 829893
, 855732
, 9029
|
|||||
| ChEBI ID |
ChEBI:2453
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [4] | ||
| MATE2 | Transporter Info | Multidrug and toxin extrusion protein 2 | Substrate | [4] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [5] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [6] | ||
| OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [7] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [8] | ||
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [6] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MATE1 | Transporter Info | Km = 2640 microM | Human embryonic kidney cells (HEK293)-MATE1 | [4] | |
| MATE2 | Transporter Info | Km = 4320 microM | Human embryonic kidney cells (HEK293)-MATE2K | [4] | ||
| OAT1 | Transporter Info | Km = 839 microM | Human embryonic kidney cells (HEK293)-OAT1 | [8] | ||
| OAT1 | Transporter Info | Km = 342 microM | Proximal tubule (S2) cells-OAT1 | [6] | ||
| OAT3 | Transporter Info | Km = 772 microM | Human embryonic kidney cells (HEK293)-OCT2 | [8] | ||
| OCT-1 | Transporter Info | Km = 151.2 microM | Proximal tubule (S2) cells-OCT1 | [6] | ||
| References | ||||||
| 1 | Acyclovir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64. | |||||
| 3 | Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80. | |||||
| 4 | Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. | |||||
| 5 | Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86. | |||||
| 6 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. | |||||
| 7 | Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8. | |||||
| 8 | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012 Mar;40(3):617-24. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.